Vaccine-induced mouse antibodies targeting Plasmodium falciparum PfVFT antigen inhibit blood stages through multiple mechanisms

Read full text Summarise with VIRAT
Authors: Yun Shan Goh, Haitong Mao, Pei Xiang Hor, Chiew Yee Loh, Zi Wei Chang, Cornelus C. Hermsen, François Henry Nosten, Robert W. Sauerwein, Laurent Rénia
Cited by: 0
References: 59

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

While vaccines are central to eradicate malaria, they remain elusive, with numerous malaria vaccine candidates showing limited efficacy in Phase II and III studies. Controlled human malaria infection studies have showed that human volunteers, immunized with Plasmodium falciparum sporozoites under drug cover, were protected experimentally from a subsequent challenge. Here, to identify new targets associated with protection, we utilized a previously developed screening approach, where we screened sera from protected and non-protected individuals against newly included hypothetical antigens in a P. falciparum antigen library. PfVFT1 was found to be associated with protection, with antibodies against PfVFT1 being detected in all protected individuals. We found that vaccine-induced mouse anti-PfVFT sera inhibited parasite reinvasion into RBCs, promoted complement deposition to induce parasite lysis, and supported phagocytosis and antibody-dependent cellular inhibition of the parasite. Together, these data indicate that PfVFT1-specific antibodies can engage multiple effector mechanisms relevant to antimalarial immunity.

Fields of Study & Subjects

Malaria Research and Control Blood groups and transfusion Monoclonal and Polyclonal Antibodies Research

Publication details

Journal / source
npj Vaccines
Volume
11
Issue
1
Pages
107
Publication date
30 March 2026
Language
EN